Merck's Oral PCSK9 Inhibitor and Nurix's BTK Degrader Among ACS First Disclosures
Other articles you may be interested in
Key Clinical Compound Updates from September 2024
This summary of September's major clinical updates features FDA approvals, drug withdrawals, anticipated regulatory decisions, notable trial results, new NDA submissions, clinical trial setbacks, and the initiation of new clinical trials.
Six Deals and Funding Rounds from July You May Have Missed
In case you missed anything while you were away on summer holiday, here’s a recap of six notable deals from July to get you up to speed.
September 2024 Molecule Roundup | >60 Molecules to Know
In this article, we present a curated selection of over 60 molecules from September that caught our attention, along with highlights of our top picks and insights into why they stand out.
August Deals and Funding Rounds Recap
In case you missed August’s business news, here’s a quick recap of five headlines, including an acquisition, three funding rounds, and a notable company closure.
Key Clinical Compound Updates from August 2024
Here’s a rundown of August’s key clinical developments, including FDA approvals, potential upcoming approvals, notable trial readouts, new NDA submissions, and pipeline realignments.